In vitro evaluation of the biological performance of macro/micro-porous silk fibroin and silk-nano calcium phosphate scaffolds.
Yan LP., Oliveira JM., Oliveira AL., Reis RL.
Animal Study, published in J Biomed Mater Res B Appl Biomater (2014) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- J Biomed Mater Res B Appl Biomater (2014)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 25164158
- DOI
- 10.1002/jbm.b.33267
Abstract (original English)
This study evaluates the biological performance of salt-leached macro/microporous silk scaffolds (S16) and silk-nano calcium phosphate scaffolds (SC16), both deriving from a 16 wt % aqueous SF solution. Enzymatic degradation results showed that the silk-based scaffolds presented desirable biostability, and the incorporation of calcium phosphate further improved the scaffolds' biostability. Human adipose tissue derived stromal cells (hASCs) were cultured onto the scaffolds in vitro. The Alamar blue assay and DNA content revealed that both scaffolds were non-cytotoxic and can support the viability and proliferation of the hASCs. Scanning electron microscopy observation demonstrated that the microporous structure was beneficial for the cell adhesion while the macroporous structure favored the cell migration and proliferation. The histological analysis displayed abundant extracellular matrix formed inside the scaffolds, leading to the significant increase of scaffolds' modulus. These results revealed that S16 and SC16 could be promising alternatives for cartilage and bone tissue engineering scaffolding applications, respectively.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.